

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/NA22E3CB6F5EN.html>

Date: December 2019

Pages: 63

Price: US\$ 2,000.00 (Single User License)

ID: NA22E3CB6F5EN

Abstracts

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2019, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen's Disease) (Genetic Disorders)

pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Overview

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Pfizer Inc

SpringWorks Therapeutics Inc

Vyriad Inc

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Drug Profiles

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Dormant Projects

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Discontinued Products

Neurofibromatosis Type I (Von Recklinghausen's Disease) - Product Development

Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen's Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by AstraZeneca Plc, H2 2019

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Pfizer Inc, H2 2019

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by SpringWorks Therapeutics Inc, H2 2019

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline by Vyriad Inc, H2 2019

Neurofibromatoses Type I (Von Recklinghausen's Disease) - Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neurofibromatosis Type I (Von Recklinghausen's Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

I would like to order

Product name: Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/NA22E3CB6F5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA22E3CB6F5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970